What is known and objective: OATP1B1 mediates the transport of a diverse range of amphiphilic organic compounds that include bile acids, steroid conjugates and hormones. This retrospective pharmacogenetic study was conducted to assess the impact of the OATP1B1 c.521T>C single nucleotide polymorphism (SNP) on the pharmacokinetics of the steroidal aromatase inhibitor drug exemestane in healthy volunteers.
| CURRENT KNOWLEDGE AND OBJECTIVE
Oestrogen-dependent breast cancers constitute the most common type of breast cancer [1] [2] [3] [4] [5] and are a leading cause of cancer-related mortality among women worldwide. 6 The steroidal aromatase inhibitor exemestane, which works by inhibiting aromatase (the rate-limiting enzyme responsible for the conversion of androgens into oestrogens in post-menopausal women), is one of the standard treatments of post-menopausal women with oestrogen-dependent breast cancers. [7] [8] [9] [10] [11] Significant interindividual variability has been observed in the clinical response to exemestane. [12] [13] [14] [15] [16] To better understand the mechanisms behind the interindividual variability in exemestane response, the metabolic pathways of exemestane were characterized, and specific enzymes responsible for the drug's disposition were identified ( Figure 1 ). These findings suggest that, after absorption, exemestane is shunted to two different primary metabolic processes. 10, [17] [18] [19] One route involves its oxidation to 6-hydroxymethylexemestane primarily by CYP3A4. The other route involves its reduction by aldoketoreductases (AKR) and CYP4A11/CYP1A
into an active (anti-oestrogenic) and bone-protective androgenic metabolite, 17-hydroexemestane, which is the major metabolite of exemestane in humans in vivo. This bone-protective androgenic metabolite is secondarily deactivated by two main enzymes, CYP3A4 and UGT2B17.
10, [17] [18] [19] [20] In this study, we hypothesize that other factors contributing to drug disposition, such as transporters (eg, organic anion-transporting polypeptides/OATP), may play a role in the pharmacokinetics of the steroidal aromatase inhibitor exemestane. The role of steroid hormones as substrates of members of the OATP family is well documented.
21-24
OATPs are a superfamily of transporter proteins that facilitate the cellular uptake of a diverse range of endogenous compounds and drugs, and are expressed in organs of importance in drug disposition, such as the liver, kidney and intestine. [25] [26] [27] [28] OATP proteins have a structure comprising 12 transmembrane domains, 29, 30 and the specific members OATP1B1 and OATP1B3 mediate the sodium-independent transport of a diverse range of amphiphilic organic compounds, including bile acids, steroid conjugates, thyroid hormones, anionic peptides, numerous drugs and other xenobiotic substances.
29,30
Although many single nucleotide polymorphisms (SNPs) have been identified in OATP1B1/3, only a few (OATP1B1 rs4149056, OATP1B1 rs2306283, OATP1B3 rs4149117 and OATP1B3 rs7311358) are known to have functional effects [30] [31] [32] and clinical significance.
To test the hypothesis that OATP1B1/3 SNPs influence the pharmacokinetics of exemestane, we retrospectively genotyped DNA samples from 14 healthy post-menopausal women for the most common
SNPs within OATP1B1/3 and correlated the genotyping results with previously published exemestane pharmacokinetic parameters. 20 
| METHODS

| Study design and subjects
This was a retrospective, non-randomized, open-label, single-dose pharmacokinetic study. Study subjects were enrolled with written informed consent under a protocol that was reviewed and approved by the Institutional Review Board at Harding University. All participants were healthy post-menopausal female volunteers who were judged to be in good medical health based on their medical history, a physical examination and blood and urinary analyses, as reported previously. 20 In preparation for the study, the subjects were asked to abstain from consuming alcoholic beverages, garlic, citrus products (especially grapefruit and grapefruit juice), apples and grapes for at least 1 week prior to the study. 
| Compliance with ethical standards
All procedures performed in the studies that involved human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
| LC-MS/MS and pharmacokinetics
Plasma concentrations of exemestane and its major metabolite 17-hydroexemestane were quantified using a previously described LC-MS/MS methodology. 20 The LC-MS/MS instrument consisted of an Agilent 1100 HPLC pump (Tokyo, Japan), a CTC Analytics HTC-PAC autosampler (Zwingen, Switzerland) and an API 4000 QTRAP MS/MS system (Toronto, Canada). The separation system included a Kinetex 2.6 μm 150×4.6 mm column (Phenomenex, Torrance, California), a security 4×3 mm guard column and a mobile phase consisting of 50% acetonitrile and 50% water at a flow rate of 500 μL/min. The mass spectrometer was operated using electrospray ionization with an ion spray voltage of 5000 V, and the temperature was set at 700°C. The positive ion multiple reaction monitoring (MRM) mode was used for the analysis and was performed using nitrogen as the collision gas. The nebulizer gas (GS1) and the turbo gas (GS2) were set at 20 V and 50 V, respectively. The declustering potential was 50 V. A dwell time of 200 milliseconds and a pause time of 5 milliseconds between the scans were used to monitor precursor/ product ion pairs. Two positive transitions (a quantifier MRM and qualifier MRM) were used for each analyte. Plasma concentrations of exemestane and 17-hydroexemestane were quantified using the ratio of the peak areas of exemestane and 17-hydroexemestane to that of the internal standard and calibration curves, which were constructed by spiking blank plasma with known amounts of exemestane and 17-hydroexemestane.
Data collection and processing were performed using the Analyst software package (version 1.6, AB SCIEX, Concord, Ontario, Canada).
| Chemicals
17-Hydroexemestane was obtained from Toronto Research Chemicals
Incorporation (Toronto, Canada). Exemestane and norgestrel (internal standard) were purchased from Sigma-Aldrich (St. Louis, MO, USA).
All other reagents were of HPLC grade or of the highest grade commercially available.
| Genotyping
Genomic DNA was extracted from whole blood using a Promega 
| Statistical analysis
Pharmacokinetic and statistical analyses were performed using 
| RESULTS AND DISCUSSION
| Clinical characteristics and OATP1B1/3 genotyping data
Fourteen healthy post-menopausal women participated in this retrospective, open-label, non-randomized pharmacokinetic study.
The subject characteristics of these healthy female volunteers are described in Table 2 Figure 5A and B).
| The impact of common OATP1B1 and OATP1B3
SNPs on exemestane and 17-hydroexemestane pharmacokinetics
This retrospective, open-label, pharmacogenetic study shows for the first time that there is an association between the OATP1B1 rs4149056C>T SNPs and exemestane metabolism in humans in vivo. In our study of 14 healthy post-menopausal female volunteers, results showed statistically significant differences in the total plasma exemestane AUC 0-8 and the 17-HEXE AUC 0-8 between the OATP1B1 rs4149056C>T genotype groups. We did not find any statistically significant differences in the total plasma exemestane AUC 0-8 or the 17-HEXE AUC 0-8 between the OATP1B1 rs2306283G>A, OATP1B3 rs4149117G>T and OATP1B3 rs7311358A>G genotype groups. These findings suggest that the OATP1B1 rs4149056C>T SNP influences the pharmacokinetics of exemestane and 17-HEXE in humans.
Our updated exemestane pharmacokinetic pathway ( Figure 6 ) now suggests that, after absorption, exemestane is first transported by the polymorphic OATP1B1 protein and then shunted to two different primary metabolic processes. 10, [17] [18] [19] One route involves its oxidation and that up to 70% of women who begin one hormonal therapy drug will be forced to discontinue and/or switch to another hormonal therapy drug due to intolerable and undesirable toxic side effects (toxic responders). 13, [38] [39] [40] The molecular basis of non-response and toxic responses could be linked to genetic variations within the organic anion-transporting polypeptides (OATPs). Our data support the strong role of OATP1B1 in the disposition of exemestane. Our findings suggest that exemestane could be even more clinically relevant than statins because our single-dose healthy volunteer pharmacokinetic study showed that the plasma AUC values of exemestane were 284% higher in rs4149056 CC+CT (82.5 ng×h/mL) individuals than in TT (29.04 ng×h/mL) homozygous individuals.
Several limitations of our study should be considered. First, this was a retrospective study that was not powered to detect a difference between the OATP1B1 rs4149056 (CC+CT) and (TT) genotype groups. Of the 14 subjects enrolled in this study, five were carriers of the minor C allele (OATP1B1 c.521 TC+CC) and the remaining nine were carriers of the OATP1B1 c.521TT genotype. A post hoc calculation using the Mann-Whitney statistical test and G*Power software version 3.1.9.2 gave a power of 51%. Second, in our study, the healthy post-menopausal female volunteers only received a single 25 mg dose of exemestane. Finally, the women were asked to abstain from the use of potential confounders such as co-medication and also herbal and dietary supplements. All of these limitations suggest that caution should be used in interpreting the results of our study and that future prospective pharmacogenetic studies are needed to validate the involvement of OATP1B1 in the disposition of the hormonal breast cancer agent exemestane.
| NEW INFORMATION AND CONCLUSION
Our data suggest that the OAPTP1B1 c.521T>C SNP may influence exemestane pharmacokinetics in humans.
